Cytokinetics Inc

CYTK

Healthcare|Biotechnology|USA

$84.87

-1.18 (-1.37%)

Upcoming Data Readouts (4)

Dec 2026

Est. completion

P4Hypertrophic Cardiomyopathy (HCM)

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Mar 2027

Est. completion

Hypertrophic Cardiomyopathy (HCM)

HCMR Re-Imaging Study

Sep 2027

Est. completion

P3Heart Failure

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Jan 2030

Est. completion

P2P3Pediatric

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM